Kamada Ltd. (KMDA) Forms $5.30 Double Bottom; Aviragen Therapeutics (AVIR) Shorts Increased By 45.61%

February 16, 2018 - By Danny Collins

Kamada Ltd. (KMDA) formed double bottom with $4.82 target or 9.00% below today’s $5.30 share price. Kamada Ltd. (KMDA) has $209.07 million valuation. The stock increased 1.92% or $0.1 during the last trading session, reaching $5.3. About 9,381 shares traded. Kamada Ltd. (NASDAQ:KMDA) has risen 73.86% since February 16, 2017 and is uptrending. It has outperformed by 57.16% the S&P500.

Aviragen Therapeutics Incorporated (NASDAQ:AVIR) had an increase of 45.61% in short interest. AVIR’s SI was 278,700 shares in February as released by FINRA. Its up 45.61% from 191,400 shares previously. With 468,500 avg volume, 1 days are for Aviragen Therapeutics Incorporated (NASDAQ:AVIR)’s short sellers to cover AVIR’s short positions. The SI to Aviragen Therapeutics Incorporated’s float is 0.91%. The stock increased 2.81% or $0.0225 during the last trading session, reaching $0.8225. About 816,249 shares traded or 65.63% up from the average. Aviragen Therapeutics, Inc. (NASDAQ:AVIR) has declined 68.31% since February 16, 2017 and is downtrending. It has underperformed by 85.01% the S&P500.

Aviragen Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options and affect patients worldwide. The company has market cap of $31.79 million. The Company’s product candidates that are in phase II clinical stage development include BTA074, an antiviral treatment for condyloma caused by human papillomavirus types 6 and 11; Vapendavir, a potent antiviral capsid binder for human rhinovirus upper respiratory infections in moderate-to-severe asthmatics; and BTA585, an oral fusion protein inhibitor for the treatment and prevention of respiratory syncytial virus infections. It currently has negative earnings. The firm also has a preclinical RSV non-fusion inhibitor program.

Among 3 analysts covering Kamada Ltd (NASDAQ:KMDA), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Kamada Ltd has $11.0 highest and $7 lowest target. $8.33’s average target is 57.17% above currents $5.3 stock price. Kamada Ltd had 6 analyst reports since November 13, 2015 according to SRatingsIntel. The rating was maintained by Jefferies with “Buy” on Tuesday, October 10. The firm earned “Buy” rating on Thursday, February 8 by H.C. Wainwright. Jefferies maintained the shares of KMDA in report on Thursday, August 10 with “Buy” rating. The rating was maintained by Jefferies on Thursday, June 22 with “Buy”.